Home
Venus Medtech

Venus Medtech Market Share Analysis for August 2026

杭州启明医疗器械股份有限公司是中国领先的经导管心脏瓣膜医疗器械企业。公司自主研发的产品venusa-valve是首个获国家药品监督管理局 (「nmpa」)批准及在中国进行商业化的经导管主动脉瓣置换术(「tavr」)产品。作为中国经导管心脏瓣膜行业的先锋，公司拥有先发优势。公司的使命是成为开发及供应结构性心脏病的经导管解决方案的开发及商业化的全球领导者。

Industry: N/A

Domainvenusmedtech.com

Year Founded2009

Employees501 - 1000

Annual Revenue$25M - $50M

Venus Medtech

Venus Medtech (including company regionals)

venusmedtech.com

See more website traffic and engagement information

Venus Medtech Revenue up to August 2026 is 25M - 50M

revenue generated by Venus Medtech top domains

Venus Medtech top domains revenue over 3 years

Revenue for Venus Medtech top domains

venusmedtech.com25M - 50M

See more with Sales Intelligence

Total visits to Venus Medtech's top domains

Understand Venus Medtech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

venusmedtech.com335

See more with Sales Intelligence

Avg. visit duration in Venus Medtech's top domains

Analyze Venus Medtech engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

venusmedtech.com00:00:56

See more with Sales Intelligence

Avg. pageviews on Venus Medtech's top domains

See how Venus Medtech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

venusmedtech.com2.19

See more with Sales Intelligence

Venus Medtech top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Venus Medtech

These are the website technologies, by industry, used by Venus Medtech top domains

Widget (3)

reCAPTCHA

Advertising (2)

PubMatic

Content Management System (2)

WordPress

Conversion & Analytics (1)

Baidu Analytics

More Technologies

4

See all

News & Signals from Venus Medtech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVenus Medtech attended event Global Partner Summit on May 26th '26.PARIS, May 26, 2026 /PRNewswire/ - Venus Medtech held its first Global Partner Summit in Paris under the motto "Insights, Innovation, Impact" and brought together sales and business partners to discuss the company's international growth strategy, the expansion of its portfolio in structural heart disease and long-term marketing priorities.

NewsEmboline, Inc. identified as competitor of Venusmedtech.Emboline has developed the Emboliner Embolic Protection System and faces Boston Scientific and Venus Medtech in the embolization protection market.

NewsVenusmedtech acquired Cardiovalve for $330M on Jan 1st '23.Notable exits include CartiHeal, acquired by Smith & Nephew (NASDAQ: SNN) for $330 million, the largest Israeli biomed exit in 2023; OutSense Diagnostics, which specializes in early detection of diseases such as colon cancer through analysis of toilet discharge and was acquired by an unnamed company; CardioValve, which specializes in catheter-based valve replacement and reduces the need for open heart surgery, was acquired by Venus Medtech (HKG: VMTHF).